A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
作者： Y-F Chen , P Jobanputra , P Barton , S Jowett , S Bryan
DOI: 10.3310/HTA10420
关键词:
摘要: OBJECTIVES This report reviews the clinical effectiveness and cost-effectiveness of adalimumab, etanercept infliximab, agents that inhibit tumour necrosis factor-alpha (TNF-alpha), when used in treatment rheumatoid arthritis (RA) adults. DATA SOURCES Electronic databases were searched up to February 2005. REVIEW METHODS Systematic literature on undertaken industry submissions National Institute for Health Clinical Excellence (NICE) reviewed. Meta-analyses data also each agent. The Birmingham Rheumatoid Arthritis Model (BRAM), a simulation model, was further developed produce an incremental analysis. RESULTS Twenty-nine randomised controlled trials (RCTs), most high quality, included. only head-to-head comparisons against methotrexate. For patients with short disease duration (
nice.org.uk 参考文章(133)
J. C. W. Edwards, G. Cambridge, Prospects for B-cell-targeted therapy in autoimmune disease Rheumatology. ,vol. 44, pp. 151- 156 ,(2005) , 10.1093/RHEUMATOLOGY/KEH446
Mark Lebwohl, Robin Blum, Eric Berkowitz, Dennis Kim, Ralph Zitnik, Cheri Osteen, Wayne Jack Wallis, No Evidence for Increased Risk of Cutaneous Squamous Cell Carcinoma in Patients With Rheumatoid Arthritis Receiving Etanercept for Up to 5 Years Archives of Dermatology. ,vol. 141, pp. 861- 864 ,(2005) , 10.1001/ARCHDERM.141.7.861
T. Sokka, T. Möttönen, P. Hannonen, Disease-modifying anti-rheumatic drug use according to the `sawtooth' treatment strategy improves the functional outcome in rheumatoid arthritis: results of a long-term follow-up study with review of the literature Rheumatology. ,vol. 39, pp. 34- 42 ,(2000) , 10.1093/RHEUMATOLOGY/39.1.34
Ferdinand C Breedveld, Tumour necrosis factor blockade in rheumatoid arthritis. Clinical Medicine. ,vol. 1, pp. 107- 109 ,(2001) , 10.7861/CLINMEDICINE.1-2-107
A. C. Verhoeven, M. Boers, P. Tugwell, Combination therapy in rheumatoid arthritis: updated systematic review. Rheumatology. ,vol. 37, pp. 612- 619 ,(1998) , 10.1093/RHEUMATOLOGY/37.6.612
Johan Askling, C Michael Fored, Eva Baecklund, Lena Brandt, Carin Backlin, Anders Ekbom, Christer Sundström, Lennart Bertilsson, Lars Cöster, Pierre Geborek, Lennart T Jacobsson, Staffan Lindblad, Jörgen Lysholm, Solbritt Rantapää-Dahlqvist, Tore Saxne, Lars Klareskog, Nils Feltelius, Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists Annals of the Rheumatic Diseases. ,vol. 64, pp. 1414- 1420 ,(2005) , 10.1136/ARD.2004.033241
David T. Felson, Jennifer J. Anderson, Maarten Boers, Claire Bombardier, Daniel Furst, Charles Goldsmith, Linda M. Katz, Robert Lightfoot, Harold Paulus, Vibeke Strand, Peter Tugwell, Michael Weinblatt, H. James Williams, Frederick Wolfe, Stephanie Kieszak, American college of rheumatology preliminary definition of improvement in rheumatoid arthritis Arthritis & Rheumatism. ,vol. 38, pp. 727- 735 ,(1995) , 10.1002/ART.1780380602
Eugene S. Chung, Milton Packer, Kim Hung Lo, Adedigbo A. Fasanmade, James T. Willerson, Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure Results of the Anti-TNF Therapy Against Congestive Heart failure (ATTACH) Trial Circulation. ,vol. 107, pp. 3133- 3140 ,(2003) , 10.1161/01.CIR.0000077913.60364.D2
Désirée van der Heijde, Robert Landewé, Lars Klareskog, Vicente Rodríguez-Valverde, Lucas Settas, Ronald Pedersen, Saeed Fatenejad, Presentation and analysis of data on radiographic outcome in clinical trials: Experience from the TEMPO study Arthritis & Rheumatism. ,vol. 52, pp. 49- 60 ,(2005) , 10.1002/ART.20775
N. P. Hurst, P. Kind, D. Ruta, M. Hunter, A. Stubbings, Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Rheumatology. ,vol. 36, pp. 551- 559 ,(1997) , 10.1093/RHEUMATOLOGY/36.5.551